Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - OncoDaily
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL / Bristol Myers Squibb, cancer, FDA,
oncodaily.com
August 10, 2025 at 7:09 PM
Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
that said, on the car-t side of things, i realized i never updated you all: both my loved ones cancer and lupus are in remission because of a car-t cell infusion called “Breyanzi®” (lisocabtagene maraleucel). that shit is good.
a loved one of mine has both lupus and a fast moving lymphoma, and will be trying CAR T-cell therapy in the near future. very very curious to see how it goes.
March 7, 2026 at 1:28 AM
that said, on the car-t side of things, i realized i never updated you all: both my loved ones cancer and lupus are in remission because of a car-t cell infusion called “Breyanzi®” (lisocabtagene maraleucel). that shit is good.
The European Commission Approves Breyanzi for Relapsed/Refractory Mantle Cell Lymphoma
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lymphoma #Breyanzi
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lymphoma #Breyanzi
The European Commission Approves Breyanzi for Relapsed/Refractory Mantle Cell Lymphoma - OncoDaily
The EU has approved Breyanzi for adults with relapsed or refractory mantle cell lymphoma after BTK inhibitor therapy, based on strong responses in TRANSCEND NHL 001.
oncodaily.com
November 26, 2025 at 9:19 PM
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules reut.rs/48vdxYK
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi.
reut.rs
December 2, 2025 at 2:30 AM
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules reut.rs/48vdxYK
Lawsuit against Bristol Myers over delayed cancer drug is revived reut.rs/4fUk3NE
Lawsuit against Bristol Myers over delayed cancer drug is revived
A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi.
reut.rs
August 13, 2026 at 5:05 PM
Lawsuit against Bristol Myers over delayed cancer drug is revived reut.rs/4fUk3NE
#3 of 5 Bristol Myers raised the price of its expensive cancer cell therapies Abecma and Breyanzi by 6% and 9%, respectively. The personalized blood cancer treatments can already cost close to half a million dollars.
January 2, 2025 at 2:23 AM
#3 of 5 Bristol Myers raised the price of its expensive cancer cell therapies Abecma and Breyanzi by 6% and 9%, respectively. The personalized blood cancer treatments can already cost close to half a million dollars.
<![CDATA[FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma ]]>
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma | PharmExec
FDA’s approval of Bristol Myers Squibb’s Breyanzi as the first CAR T therapy for relapsed or refractory marginal zone lymphoma underscores the therapy’s expanding leadership in B-cell malignancies, backed by compelling Phase II data
www.pharmexec.com
December 6, 2025 at 1:19 AM
<![CDATA[FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma ]]>
this bit is particularly nauseating. “potentially transformative” — what a horrid PR-speak way to say “it’ll literally save your life so of course we’re going to price it at half a megabuck”
January 2, 2025 at 4:20 AM
this bit is particularly nauseating. “potentially transformative” — what a horrid PR-speak way to say “it’ll literally save your life so of course we’re going to price it at half a megabuck”
BMS fleshes out Breyanzi results in marginal zone lymphoma $BMY firstwordpharma.com/story/5973120
June 16, 2025 at 9:35 PM
BMS fleshes out Breyanzi results in marginal zone lymphoma $BMY firstwordpharma.com/story/5973120
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma
www.nice.org.uk
February 20, 2025 at 2:14 PM
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
EC expands approval for Breyanzi for r/r FL
https://cancerletter.com/drugs-and-targets/20250321_10b/
https://cancerletter.com/drugs-and-targets/20250321_10b/
EC expands approval for Breyanzi for r/r follicular lymphoma - The Cancer Letter
The European Commission has granted approval to Breyanzi, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register […]
cancerletter.com
March 25, 2025 at 3:00 PM
EC expands approval for Breyanzi for r/r FL
https://cancerletter.com/drugs-and-targets/20250321_10b/
https://cancerletter.com/drugs-and-targets/20250321_10b/
"AND, STARTING AT LEFT INSIDE LINEBACKER, FRESH OFF HIS LATEST BREYANZI INFUSION FOR LYMPHOMA, HE'S FACING THE REAPER, HE DOESN'T FEAR OFFENSIVE LINEMEN, IT'S BBBBEEEEEEEENNNNNJYYYYY FFFRIEEEEEEDMAAAANNNN!!!!!"
September 9, 2026 at 2:38 PM
"AND, STARTING AT LEFT INSIDE LINEBACKER, FRESH OFF HIS LATEST BREYANZI INFUSION FOR LYMPHOMA, HE'S FACING THE REAPER, HE DOESN'T FEAR OFFENSIVE LINEMEN, IT'S BBBBEEEEEEEENNNNNJYYYYY FFFRIEEEEEEDMAAAANNNN!!!!!"
Former #USMNT Kasey Keller privately battled non-Hodgkin lymphoma. He underwent 13 treatments before becoming one of the first patients to receive Breyanzi CAR T cell therapy. Thankfully, he is in full remission. He shares his health journey for the first time: ⬇️
athlonsports.com/soccer/inter...
athlonsports.com/soccer/inter...
US Soccer Legend Kasey Keller Reveals Life-Changing Health Update
Former USMNT goalkeeper and soccer analyst Kasey Keller detailed his previously undisclosed cancer battle for the first time in an interview with Athlon Sports.
athlonsports.com
February 4, 2026 at 12:03 PM
Former #USMNT Kasey Keller privately battled non-Hodgkin lymphoma. He underwent 13 treatments before becoming one of the first patients to receive Breyanzi CAR T cell therapy. Thankfully, he is in full remission. He shares his health journey for the first time: ⬇️
athlonsports.com/soccer/inter...
athlonsports.com/soccer/inter...
The FDA just approved the CAR T cell therapy lisocabtagene maraleucel for adults with relapsed or refractory marginal zone #lymphoma. Congratulations to study investigator M. Lia Palomba! #lymsm @mskcancercenter.bsky.social
FDA approves lisocabtagene maraleucel for relapsed or refractory margi
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for
www.fda.gov
December 5, 2025 at 4:19 PM
The FDA just approved the CAR T cell therapy lisocabtagene maraleucel for adults with relapsed or refractory marginal zone #lymphoma. Congratulations to study investigator M. Lia Palomba! #lymsm @mskcancercenter.bsky.social
→ La catégorie la plus importante est celle des maladies #Hématologiques 🩸, qui couvrent des maladies comme le #Lymphome, le #MyélomeMultiple et l’ #Hémophilie
→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi
→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi
November 6, 2025 at 5:46 AM
→ La catégorie la plus importante est celle des maladies #Hématologiques 🩸, qui couvrent des maladies comme le #Lymphome, le #MyélomeMultiple et l’ #Hémophilie
→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi
→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi
"Bristol Myers raised the price of its expensive cancer cell therapies Abecma and Breyanzi by 6% and 9%, respectively. The personalized blood cancer treatments can already cost close to half a million dollars."
But they need more.
Really, do they?
But they need more.
Really, do they?
January 1, 2025 at 4:40 PM
"Bristol Myers raised the price of its expensive cancer cell therapies Abecma and Breyanzi by 6% and 9%, respectively. The personalized blood cancer treatments can already cost close to half a million dollars."
But they need more.
Really, do they?
But they need more.
Really, do they?
pharmaceutical companies raised prices on over 800 drugs this year by an average price of increase of 4%. Kisqali, a cancer drug is now $19,100. Breyanzi is up 9% to $531,350 per treatment. The orange menace is hard at work fucking up the country.
January 28, 2025 at 12:08 PM
pharmaceutical companies raised prices on over 800 drugs this year by an average price of increase of 4%. Kisqali, a cancer drug is now $19,100. Breyanzi is up 9% to $531,350 per treatment. The orange menace is hard at work fucking up the country.
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
reut.rs
December 1, 2025 at 10:01 PM
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
Fri news: CDC advisors vote to overturn pediatric hep B vax policy. Eisai confident in anti-tau asset. BMS Breyanzi is first CAR-T for marginal zone lymphoma. Praxis soars on rare childhood epilepsy trial data. CHS sells lab assets to Labcorp. —https://bit.ly/3JeBlY5
December 5, 2025 at 5:17 PM
Fri news: CDC advisors vote to overturn pediatric hep B vax policy. Eisai confident in anti-tau asset. BMS Breyanzi is first CAR-T for marginal zone lymphoma. Praxis soars on rare childhood epilepsy trial data. CHS sells lab assets to Labcorp. —https://bit.ly/3JeBlY5
El SAS inicia la compra de un medicamento de vanguardia contra el mieloma múltiple que se suministrará en el Reina Sofía dozz.es/vhjza5
El SAS inicia la compra de un medicamento de vanguardia contra el mieloma múltiple que se suministrará en el Reina Sofía
El centro cordobés es uno de los tres hospitales andaluces autorizados por el Ministerio de Sanidad para dispensar Breyanzi, un tratamiento inmunocelular de alta complejidad
dozz.es
April 15, 2026 at 7:05 AM
El SAS inicia la compra de un medicamento de vanguardia contra el mieloma múltiple que se suministrará en el Reina Sofía dozz.es/vhjza5
Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
https://www.medpagetoday.com/hematologyoncology/lymphoma/118859
https://www.medpagetoday.com/hematologyoncology/lymphoma/118859
First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light
Lisocabtagene maraleucel achieved a 95.5% response rate in patients with relapsed/refractory MZL
www.medpagetoday.com
December 7, 2025 at 12:50 AM
Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
https://www.medpagetoday.com/hematologyoncology/lymphoma/118859
https://www.medpagetoday.com/hematologyoncology/lymphoma/118859
Glad to be back in hockey season (#gohabsgo) but good lord the ads on ESPN are bleak.
- hair growth supplement
- gambling apps
- teaser for a “documentary” that’s paid for by Bristol-Myers Squibb as a CAR-T cell (Breyanzi) therapy success story* [which you have to search online to find out]
1/
- hair growth supplement
- gambling apps
- teaser for a “documentary” that’s paid for by Bristol-Myers Squibb as a CAR-T cell (Breyanzi) therapy success story* [which you have to search online to find out]
1/
September 30, 2026 at 1:48 AM
Glad to be back in hockey season (#gohabsgo) but good lord the ads on ESPN are bleak.
- hair growth supplement
- gambling apps
- teaser for a “documentary” that’s paid for by Bristol-Myers Squibb as a CAR-T cell (Breyanzi) therapy success story* [which you have to search online to find out]
1/
- hair growth supplement
- gambling apps
- teaser for a “documentary” that’s paid for by Bristol-Myers Squibb as a CAR-T cell (Breyanzi) therapy success story* [which you have to search online to find out]
1/
BMS Q2 2026: Opdivo down, Breyanzi +41%, Eliquis up. Growth Portfolio $13.8B vs Legacy $5.4B. Net debt down 7%. AI push with NVIDIA & Anthropic aims to boost drug discovery. Full deep dive: https://post.kapualabs.com/dvureppt #BMS #NVIDIA #Anthropic #AI #Pharma #Biotech
BMS Q2 2026: Growth Portfolio Rises, Legacy Declines
A granular analysis of revenue mix, earnings-quality adjustments, and whether growth drugs can offset Legacy erosion.
nova.kapualabs.com
August 12, 2026 at 11:19 AM
BMS Q2 2026: Opdivo down, Breyanzi +41%, Eliquis up. Growth Portfolio $13.8B vs Legacy $5.4B. Net debt down 7%. AI push with NVIDIA & Anthropic aims to boost drug discovery. Full deep dive: https://post.kapualabs.com/dvureppt #BMS #NVIDIA #Anthropic #AI #Pharma #Biotech
Just under 600 lymphoma patients per year could benefit from new treatment with NHS England to make funding available within 90days. In the interim, funding will be available from the Cancer Drugs Fund
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma
www.nice.org.uk
February 21, 2025 at 1:15 AM
Just under 600 lymphoma patients per year could benefit from new treatment with NHS England to make funding available within 90days. In the interim, funding will be available from the Cancer Drugs Fund
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...